Myriad Genetics (MYGN) EBITDA (2009 - 2026)

Myriad Genetics has disclosed EBITDA across 18 years of filings, most recently posting -$30.7 million for Q1 2026.

• In Q1 2026, EBITDA fell 5.86% year-over-year to -$30.7 million; the TTM figure through Mar 2026 stood at -$388.9 million (down 212.37% YoY), while the FY2025 annual figure was -$387.2 million, down 213.52% from the prior year.
• EBITDA declined to -$30.7 million in Q1 2026, from -$5.7 million in the prior quarter.
• Over the last five years, EBITDA for MYGN reached as high as -$5.7 million in Q4 2025 and fell as low as -$329.2 million in Q2 2025.
• The 5-year median for EBITDA is -$31.4 million (2023), against an average of -$55.3 million.
• The widest YoY moves for EBITDA: up 85.38% in 2025, down 801.92% in 2025.
• A 5-year view of EBITDA shows it stood at -$52.2 million in 2022, then surged by 39.85% to -$31.4 million in 2023, then dropped by 24.2% to -$39.0 million in 2024, then soared by 85.38% to -$5.7 million in 2025, then tumbled by 438.6% to -$30.7 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$30.7 million, -$5.7 million, and -$23.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.